Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Caregiver Burden 1Breast Neoplasms 1

Interventions

Gemcitabine 69Fluorouracil 44pembrolizumab 43Oxaliplatin 42Capecitabine 40Bevacizumab 37Leucovorin 36Irinotecan 31Cisplatin 27Nivolumab 24Paclitaxel 21Cetuximab 21Panitumumab 20130-nm albumin-bound paclitaxel 20Sorafenib 18Albumin-Bound Paclitaxel 18Drug Therapy 15Docetaxel 15Cyclophosphamide 15Radiotherapy 14Blood Specimen Collection 14IFL protocol 12atezolizumab 11Exercise 11Taxes 10budigalimab 9Erlotinib Hydrochloride 9trametinib 8Folfox protocol 8Carboplatin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Health Resources × Gastrointestinal × Clear all
NCT04685551 2022-07-26

Improving Survivorship Among Minority Cancer Dyads

Charles Drew University of Medicine and Science

Phase NA Withdrawn
BreastGastrointestinalThoracic

Caregiver Burden, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡